Literature DB >> 14692032

Prolonged survival after complete resection of metastases from intraocular melanoma.

Eddy C Hsueh1, Richard Essner, Leland J Foshag, Xing Ye, He-Jing Wang, Donald L Morton.   

Abstract

BACKGROUND: The median survival time is only 2-6 months after a diagnosis of metastases from intraocular melanoma. Because complete resection of metastatic melanoma from a cutaneous primary tumor can prolong survival, the authors hypothesized that resection also might benefit patients with metastases from an intraocular site.
METHODS: From 1971 to 1999, 112 patients with metastatic melanoma from an intraocular site were enrolled in various treatment protocols after informed consent was obtained. Prospectively recorded clinical variables and follow-up information were retrieved from the patient database. Survival curves were estimated using the Kaplan-Meier method. Univariate analysis was performed with the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model. Propensity score analysis was used to reduce the imbalance between subgroups and to assess treatment effect.
RESULTS: Seventy-eight patients (70%) presented with liver involvement. Twenty-four patients (21%) underwent resection of metastatic lesions. At a median follow-up time of 11 months (range, 1-97 months; > 36 months for survivors), the median survival period was 11 months and the 5-year survival rate was 7%. Univariate analysis showed that surgical resection, site of metastases, number of metastatic lesions, and disease-free interval were correlated significantly with survival (P < 0.001, P < 0.001, P < 0.001, and P = 0.031, respectively). Multivariate analysis showed that surgical resection was significant (P = 0.008) but that the site of metastases was not (P = 0.146). The median survival and the 5-year survival rate were 38 months and 39%, respectively, for surgical patients, versus 9 months and 0%, respectively, for nonsurgical patients. After adjusting for covariate imbalance by propensity score analysis, surgery remained significant (P = 0.021) on multivariate analysis.
CONCLUSIONS: Complete resection may prolong survival in certain patients with distant metastases from intraocular primary melanoma. However, the overall unfavorable prognosis indicates an urgent need for more effective nonsurgical interventions. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 14692032     DOI: 10.1002/cncr.11872

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.

Authors:  Joseph Kim; Takuji Mori; Steven L Chen; Farin F Amersi; Steve R Martinez; Christine Kuo; Roderick R Turner; Xing Ye; Anton J Bilchik; Donald L Morton; Dave S B Hoon
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Selected patients with metastatic melanoma may benefit from liver resection.

Authors:  Paulo Herman; Marcel Autran C Machado; André Luis Montagnini; Luiz A C D'Albuquerque; William A Saad; Marcel C C Machado
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

3.  High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Authors:  Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

4.  Applying propensity score methods in medical research: pitfalls and prospects.

Authors:  Zhehui Luo; Joseph C Gardiner; Cathy J Bradley
Journal:  Med Care Res Rev       Date:  2010-05-04       Impact factor: 3.929

Review 5.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

Review 6.  Transhepatic therapies for metastatic uveal melanoma.

Authors:  David J Eschelman; Carin F Gonsalves; Takami Sato
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

7.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

8.  [Metastatic malignant choroidal melanoma: a case report about 18 years with palliative operative treatment].

Authors:  T Prietzel; I Haferkorn; A Macher; E Schumann; G von Salis-Soglio; T Aigner
Journal:  Orthopade       Date:  2009-03       Impact factor: 1.087

9.  Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.

Authors:  K Strobel; B Bode; R Dummer; P Veit-Haibach; D R Fischer; L Imhof; S Goldinger; Hans C Steinert; G K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

10.  Quality of evidence about effectiveness of treatments for metastatic uveal melanoma.

Authors:  James J Augsburger; Zélia M Corrêa; Adeel H Shaikh
Journal:  Trans Am Ophthalmol Soc       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.